Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mxOlczKGh? NWXVdmduTE2VTx?= NIfDO4xKSzVyPUCuNFAxODdizszN MkfJNVc6PTZyOEC=
K562 M{HN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HkcVczKGh? MVjEUXNQ Mn33TWM2OD1yLkCwNUDPxE1? NEXwTI8yPzl3NkC4NC=>
M07e NHjRTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXFO|IhcA>? NF3IN3hFVVOR NF\RXZRKSzVyPUCuNFAyOiEQvF2= MV[xO|k2PjB6MB?=
ALL3 M3f6ZmN6fG:2b4jpZ{BCe3OjeR?= MVSwMlHPxE1? MXm3NkBp MXrEUXNQ MlnMTWM2OD1yLkCwNFQh|ryP NGL2[|QyQTh6OUW0NC=>
CML M1fFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;GNWIzOCCvaX6= NFTvcHFFVVOR NGLmcmNKSzVyPUCuNFAyKM7:TR?= MkDTNVkzOTlyMU[=
BA/F3 NG\oclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf0O|IhcA>? NWj3ZmNuTE2VTx?= NIrW[W5KSzVyPU[uOVg6KM7:TR?= MmfuNlMxQDh4NES=
BA/F3 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjWbnQ4OiCq MUjEUXNQ MnzTTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= NYjV[5c1OjNyOEi2OFQ>
BA/F3 NGe5WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjjbXZEPzJiaB?= M4fqVmROW09? NGLvc3RKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP M3\LSVI{ODh6NkS0
BA/F3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnOW284OiCq M37qWGROW09? MWPJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? MXmyN|A5QDZ2NB?=
BA/F3 M2PGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NkBp M{PaXWROW09? MULJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? MoXKNlM{ODF5MEO=
BA/F3 M2ezfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq3NkBp MV7EUXNQ NYnTenRyUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= NFTGeYwzOzNyMUewNy=>
BA/F3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3NkBp MWDEUXNQ NXPwbYNqUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= NVu1eYFNOjN|MEG3NFM>
BA/F3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPCUZM{PzJiaB?= M4\4ZWROW09? MULJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO NFvDOZAzOzNyMUewNy=>
BA/F3 NWnoTFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j0cVczKGh? M1HOfGROW09? M2jHfmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP NUXqW4xNOjN|MEG3NFM>
BA/F3 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\jO|IhcA>? MX\EUXNQ M2iwb2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NFftdXYzOzNyMUewNy=>
BA/F3 NV;nVHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PBUVczKGh? NGThb5pFVVOR MXLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? MlTrNlM{ODF5MEO=
BA/F3 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPKbZJvPzJiaB?= NG\kcWpFVVOR M2Tr[Glv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO M2[3S|I{OzBzN{Cz
BA/F3 M3nl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELhN484OiCq NX\CfGdETE2VTx?= NFnBZ2ZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= Mli2NlM{ODF5MEO=
T cell NWC0ZVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjwTZE4OiCq M3;1SWROW09? M3P5WmlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO MlzzNVcyPTR3MUK=
WiDr MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknTO|IhcA>? NX;OXZhsTE2VTx?= NVnMRVFUUUN3ME2wMlA2OiEQvF2= Mme4NVU3OTV3MUK=
PC3 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHuflc4OiCq MVfEUXNQ NVz3V3FVUUN3ME2wMlAxQTRizszN NXzjWVlwOTV4MUW1NVI>
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm3SVM4OiCq MlLJSG1UVw>? MkThTWM2OD1yLkCxNkDPxE1? M{\yR|E2PjF3NUGy
Hs578T MkjSR5l1d3SxeHnjJGF{e2G7 M3G5fFczKGh? NVLwT3N5TE2VTx?= NYnScWF{T0l3ME2wMlA{KM7:TR?= MVeyOFAyPTN{Nx?=
HMEC NYexS4F[S3m2b4TvfIlkKEG|c3H5 MUi3NkBp NVTOU2t7TE2VTx?= M1XuXmdKPTB;MT64JO69VQ>? NFzkZmUzPDBzNUOyOy=>
DU145 MU\DfZRwfG:6aXOgRZN{[Xl? NH7UPYg4OiCq NVmxdWI6TE2VTx?= NHrmT5hIUTVyPUCuNVYh|ryP MVSyOFAyPTN{Nx?=
U251 NGTXVm9EgXSxdH;4bYMhSXO|YYm= Mnr0O|IhcA>? M3jGVWROW09? M1HvcWdKPTB;Mj64NUDPxE1? NFzrW4IzPDBzNUOyOy=>
NCI60 MmKzR5l1d3SxeHnjJGF{e2G7 NVzjc5AxPzJiaB?= M4PaZWROW09? NIThPG5IUTVyPUWuO{DPxE1? NFnFNZozPDBzNUOyOy=>
MALME-3M NH7x[IdEgXSxdH;4bYMhSXO|YYm= M13qSFczKGh? MXfEUXNQ MmnJS2k2OD14Lk[xJO69VQ>? MXWyOFAyPTN{Nx?=
KM12 NGXTNXlEgXSxdH;4bYMhSXO|YYm= NYD1OZFEPzJiaB?= NIHzcY9FVVOR MUHHTVUxRTdwNESg{txO NVnkUHFIOjRyMUWzNlc>
SW620 NEPlVpVEgXSxdH;4bYMhSXO|YYm= MXu3NkBp NGrJZY9FVVOR NWHHWGNiT0l3ME24MlQ{KM7:TR?= NVnpWmp1OjRyMUWzNlc>
RXF 393NL NVzZTVE6S3m2b4TvfIlkKEG|c3H5 NYfjRlI2PCCmYYnz MYLEUXNQ M1LhemlEPTB;MD6wNlE4KM7:TR?= NVvwd5BiOjN{NUOwO|Q>
LXFA 983L NEHyVWFEgXSxdH;4bYMhSXO|YYm= MnfjOEBl[Xm| M3O0VWROW09? M3LR[GlEPTB;MD6wOVY2KM7:TR?= MmHtNlMzPTNyN{S=
PRXF DU145 Mor5R5l1d3SxeHnjJGF{e2G7 MnrVOEBl[Xm| NX3oOW86TE2VTx?= NHvSOVJKSzVyPUCuNFYzOyEQvF2= NGX3OFczOzJ3M{C3OC=>
PAXF 1657L MXnDfZRwfG:6aXOgRZN{[Xl? MofGOEBl[Xm| NELZTZJFVVOR MX\JR|UxRTBwMUKxJO69VQ>? MmrvNlMzPTNyN{S=
CXF 1103L M3q0RmN6fG:2b4jpZ{BCe3OjeR?= M3vDeFQh\GG7cx?= NHLkVFdFVVOR MUnJR|UxRTRwM{[g{txO NH;HTpkzOzJ3M{C3OC=>
GXF251L M4XpemN6fG:2b4jpZ{BCe3OjeR?= MXK0JIRigXN? NITIO45FVVOR MnXZTWM2OD1{LkK1JO69VQ>? NEHoZYkzOzJ3M{C3OC=>
NCI-H23 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NkBp MkHUSG1UVw>? MWTJR|UxRTJwMkeg{txO MWiyN|UzOTB{MB?=
HCT116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:zN|czKGh? MnTvSG1UVw>? MnfPTWM2OD1{LkOg{txO NF\YUWozOzV{MUCyNC=>
MCF7 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXndXA4OiCq M2fWfmROW09? NWXjRYFEUUN3ME2yMlU4KM7:TR?= NF[1bYEzOzV{MUCyNC=>
NCI-H460 M165S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne3O|IhcA>? MYXEUXNQ MXHJR|UxRThwOUmg{txO NEflblMzOzV{MUCyNC=>
DLD1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnac5ZkPzJiaB?= MoezSG1UVw>? NHHIOW5KSzVyPUSuOkDPxE1? NYjNOmxTOjN3Nke5OlA>
NCI-H661 M33xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPBO|IhcA>? M3TKUGROW09? M4W3SWlEPTB;Nz64JO69VQ>? NILzTXAzOzV4N{m2NC=>
A549 M2jlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\LTJk4OiCq M3zpWWROW09? MkTBTWM2OD16LkKg{txO MnLzNlM2Pjd7NkC=
U937 MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi3fII4OiCq NVnzU4dLTE2VTx?= MXLJR|UxRTF{LkKg{txO M3nQ[|I{PTZ5OU[w
HEK293 MWTGeY5kfGmxbjDBd5NigQ>? MkjpNVDDqM7:TR?= MXvEUXNQ M4C4VWlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN MXuyNlc4ODZzMB?=
HUVEC NUfIdmVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXJR4EzOC5zNdMg{txO NILyenI4OiCq NHS2e4dFVVOR MoXyTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN MlOyNlI5PTN7OUO=
HUVEC NG\uXppHfW6ldHnvckBCe3OjeR?= NF\RfVgyPcLizszN NV;qSY95PzJiaB?= NFfob2xFVVOR MY\JcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> NHrGUZMzOjh3M{m5Ny=>
Plasmodium falciparum NYHhTIpVTnWwY4Tpc44hSXO|YYm= M2PRbFExyqEQvF2= Mof2NVUhdWmw MV\EUXNQ NU\aWGxPUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP NVHNb3Z2OjR3NUCzN|A>
PC3 NWrsWlluTnWwY4Tpc44hSXO|YYm= NEX0S4YxNjFizszN MUm1JIg> Mm\DSG1UVw>? MoTITY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P MnrsNVk1PjJ7N{W=
DU145 MmjySpVv[3Srb36gRZN{[Xl? NHvzdFMxNjFizszN M{j4NFUhcA>? M1yzbGROW09? NHvuUmNKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> MYCxPVQ3Ojl5NR?=
PC3 NF[ybY1McW6jc3WgRZN{[Xl? NHXLN2kxNjFizszN Ml\qOUBp MlrCSG1UVw>? NX\DNFQyUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> M2HEcVE6PDZ{OUe1
DU145 Mny1T4lv[XOnIFHzd4F6 M{TmUFAvOSEQvF2= NIDYRpk2KGh? NWnITI1MTE2VTx?= M3m1ZWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NYLzO2tpOTl2NkK5O|U>
PC3 Ml34T4lv[XOnIFHzd4F6 NVXD[GVkOC5zIN88US=> Mnu5OUBp NWnKUGlSTE2VTx?= M{DHemlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NEXVU5EyQTR4Mkm3OS=>
DU145 NEn6eo5McW6jc3WgRZN{[Xl? MlXJNE4yKM7:TR?= NIXp[Ws2KGh? NVHrfYprTE2VTx?= MlL6TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NFHCT|EyQTR4Mkm3OS=>
Huh7 NUTvVYN[SW62aY\pdoFtKEG|c3H5 M1i1e|IvPSEQvF2= NXn2fI9tPCCmYYnz NUfSW2dnTE2VTx?= MXfJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MofGNVc{PjB4N{[=
C6/36 MoCwRY51cX[rcnHsJGF{e2G7 MX[yMlUh|ryP MVe0JIRigXN? Mom3SG1UVw>? MW\Jcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO Ml[0NVc{PjB4N{[=
U937 MYXGeY5kfGmxbjDBd5NigQ>? NUHFfI81OSEQvF2= NWrjTYtbOSCq MUfEUXNQ NYjGZ5MyWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= M1n5WVE4Pjh2MEm5
U937 NVjKSIdpTnWwY4Tpc44hSXO|YYm= MkTYNUDPxE1? MlvyNUBp NELkXmpFVVOR MV3S[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> MXuxO|Y5PDB7OR?=
murine mast cell NWnLO|RETnWwY4Tpc44hSXO|YYm= MmLMNUDPxE1? NIW5coQzPCCq MoPaSG1UVw>? NGXtTZBKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= NEfQUlIyPzZ6NEC5PS=>
BV-173 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkOzTWM2OD1yLkCwNFAxODFyOTFOwG0> M3e5OHNCVkeHUh?=
K-562 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMECwNFAxOjZ4IN88US=> MWXTRW5ITVJ?
BL-70 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrMZ4ZlUUN3ME2wMlAxODByMEiyNkDPxE1? NXPLXGJSW0GQR1XS
EM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrzTWM2OD1yLkCwNFAxOTB6IN88US=> MmDJV2FPT0WU
LAMA-84 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDYZYxQUUN3ME2wMlAxODByM{KxJO69VQ>? NFT4bWdUSU6JRWK=
MEG-01 NFrOb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMECwNFA6QCEQvF2= MW\TRW5ITVJ?
EoL-1-cell MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrVe3hYUUN3ME2wMlAxODBzM{Gg{txO MXHTRW5ITVJ?
CTV-1 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G4UGlEPTB;MD6wNFAxPDB2IN88US=> M2fDR3NCVkeHUh?=
TE-15 NYi2NZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEC1PFkh|ryP MlX6V2FPT0WU
NOS-1 NF3ITGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXhTHZKSzVyPUCuNFA3OTNizszN M{H4XnNCVkeHUh?=
D-336MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHDT45KSzVyPUCuNFA3OyEQvF2= NXXKeZZpW0GQR1XS
LB1047-RCC NULZbXFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEixRlRKSzVyPUCuNFA6QDlizszN NUXC[45QW0GQR1XS
LB996-RCC M2fhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{flTWlEPTB;MD6wNFk6OSEQvF2= M{\2bHNCVkeHUh?=
SW982 NXroW2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEGxNVUh|ryP MlX2V2FPT0WU
TK10 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0XGNKSzVyPUCuNFEyPzRizszN NWT1b|FVW0GQR1XS
A704 M2q0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT6TWM2OD1yLkCxOFkyKM7:TR?= NYfLV2ZQW0GQR1XS
TE-8 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS0TWM2OD1yLkCxOVc3KM7:TR?= NH64RlVUSU6JRWK=
DOHH-2 NIPzbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV73dHBFUUN3ME2wMlAyPzF7IN88US=> M1L0eXNCVkeHUh?=
HOP-62 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;0OZNPUUN3ME2wMlAyQDN2IN88US=> MXnTRW5ITVJ?
TE-12 NYPXW4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEG4OlEh|ryP NUHrOYo5W0GQR1XS
KGN MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n6cGlEPTB;MD6wNVk1OiEQvF2= M1nrZ3NCVkeHUh?=
NCI-H1648 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES1b|JKSzVyPUCuNFIxOTFizszN NIXUTGdUSU6JRWK=
OS-RC-2 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEKwN{DPxE1? MV3TRW5ITVJ?
GB-1 NIjKZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyUnBKSzVyPUCuNFIyPTdizszN MmrRV2FPT0WU
RXF393 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\DR2lEPTB;MD6wNlM2PyEQvF2= Mk\aV2FPT0WU
LC-2-ad MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jZXGlEPTB;MD6wNlU5PiEQvF2= MXjTRW5ITVJ?
KS-1 NEjp[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC1SG1KSzVyPUCuNFI4OyEQvF2= MUDTRW5ITVJ?
ETK-1 NFLvWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rVPWlEPTB;MD6wNlg{OiEQvF2= NIHsT25USU6JRWK=
SW954 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXNTWM2OD1yLkCyPVI4KM7:TR?= NXPBdHBGW0GQR1XS
Becker NV;QRZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\3[YpKSzVyPUCuNFMxODNizszN NXr0WYxCW0GQR1XS
MZ1-PC Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXETWM2OD1yLkCzNVE6KM7:TR?= NYL6dnUyW0GQR1XS
ES6 NIG5cG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHiN25KSzVyPUCuNFMyQTNizszN M3jhS3NCVkeHUh?=
KURAMOCHI NHLMV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzGRWJKSzVyPUCuNFM1QDdizszN MV3TRW5ITVJ?
CGTH-W-1 NUXDUYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHC[GxKSzVyPUCuNFM2PDhizszN M3vrOnNCVkeHUh?=
VA-ES-BJ NVHSOW1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HCbWlEPTB;MD6wN|kxOiEQvF2= MlL2V2FPT0WU
LXF-289 M2DENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEO5OVYh|ryP NF\Mbm1USU6JRWK=
MPP-89 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXVb|ZKSzVyPUCuNFQxPDlizszN MXfTRW5ITVJ?
SW872 NFTBPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMESxOlEh|ryP NVy3T3ZiW0GQR1XS
SNB75 NHjC[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\kfY1KSzVyPUCuNFQ1OzVizszN MVTTRW5ITVJ?
PSN1 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nlVWlEPTB;MD6wOFQ4PCEQvF2= MlPxV2FPT0WU
LB831-BLC MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHITWM2OD1yLkC0OlA6KM7:TR?= MYPTRW5ITVJ?
MFH-ino NWPMZZRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HHNmlEPTB;MD6wOFczPCEQvF2= M4LvTHNCVkeHUh?=
TGBC24TKB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1noWmlEPTB;MD6wOFc3OSEQvF2= MmrqV2FPT0WU
A388 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEWwPVUh|ryP NVuzeppmW0GQR1XS
BB30-HNC NXvWeGZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n4OGlEPTB;MD6wOVQ{PyEQvF2= M3L6cHNCVkeHUh?=
GI-ME-N NILDV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXQTWM2OD1yLkC2NVE5KM7:TR?= NGm1Z25USU6JRWK=
TGBC1TKB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSW45KSzVyPUCuNFYyPjRizszN M4XNPHNCVkeHUh?=
TE-10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\qeWNKSzVyPUCuNFY{PTdizszN M1PDenNCVkeHUh?=
A498 NH:zSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj0SW5jUUN3ME2wMlA4Ojh2IN88US=> M3zmSnNCVkeHUh?=
TE-11 NVXne4hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof0TWM2OD1yLkC3PFU5KM7:TR?= MXHTRW5ITVJ?
BB65-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjjZ|dKSzVyPUCuNFgzOjdizszN NEPlU3RUSU6JRWK=
C2BBe1 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;VTWlKSzVyPUCuNFg{ODhizszN M{HsR3NCVkeHUh?=
NCI-H747 NFP1XVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEizOlIh|ryP MmTWV2FPT0WU
IST-MES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Nb4hvUUN3ME2wMlA5PTV{IN88US=> MVrTRW5ITVJ?
KALS-1 NFX1N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnaTWM2OD1yLkC5OFkh|ryP M3vSTHNCVkeHUh?=
GCIY MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK5ZZFXUUN3ME2wMlA6PjV4IN88US=> M1O5c3NCVkeHUh?=
RL95-2 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK1[G5TUUN3ME2wMlExOzhizszN MYLTRW5ITVJ?
TE-1 NFzuXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUC1OEDPxE1? MX\TRW5ITVJ?
NCI-H1355 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH6[pBlUUN3ME2wMlEyODJ6IN88US=> NUDyT3RuW0GQR1XS
SW962 NUna[2dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT4VIZKSzVyPUCuNVEzQTJizszN MU\TRW5ITVJ?
KLE MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC5bFBkUUN3ME2wMlEyOzF5IN88US=> NHXiN|VUSU6JRWK=
MC116 M{S0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\lRVFKSzVyPUCuNVE1OSEQvF2= M3jyPXNCVkeHUh?=
NMC-G1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMUG2NFYh|ryP NGLZWJBUSU6JRWK=
KU812 MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qwR2lEPTB;MD6xNVg5OyEQvF2= M2LoS3NCVkeHUh?=
COLO-829 M3HSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMUKyNVMh|ryP NYizdZg3W0GQR1XS
NTERA-S-cl-D1 NGDkZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOXmlEPTB;MD6xNlI5OyEQvF2= MnriV2FPT0WU
IST-MEL1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr3XGhKSzVyPUCuNVM1PSEQvF2= M4rWOXNCVkeHUh?=
MLMA Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMUSwN|Ih|ryP M3XkTXNCVkeHUh?=
LS-123 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMUSwOlQh|ryP NHzie5FUSU6JRWK=
LB2518-MEL MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUSxOlIh|ryP MkTIV2FPT0WU
NB69 M2HrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH0[HdCUUN3ME2wMlE1PDN4IN88US=> MVrTRW5ITVJ?
8-MG-BA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\OW5BOUUN3ME2wMlE2PDV6IN88US=> M2LjcXNCVkeHUh?=
K5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfJTWM2OD1yLkG2OFg6KM7:TR?= NG\nXndUSU6JRWK=
KINGS-1 NXvxUYtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3hR3lKSzVyPUCuNVY3PjZizszN MkD4V2FPT0WU
SF268 NG\yVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLLTWM2OD1yLkG3OFA1KM7:TR?= NF73PJBUSU6JRWK=
PF-382 NHvCW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnzdWNyUUN3ME2wMlE4Pjd6IN88US=> Mn6yV2FPT0WU
SH-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvSTWM2OD1yLkG4OFE{KM7:TR?= NXnQOHh2W0GQR1XS
NALM-6 NVjjW486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rsUGlEPTB;MD6xPVI6PSEQvF2= NGi0SoJUSU6JRWK=
CP66-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3QTWM2OD1yLkG5OVMyKM7:TR?= M4\ScnNCVkeHUh?=
697 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorGTWM2OD1yLkG5PVg4KM7:TR?= M2DPRnNCVkeHUh?=
CP67-MEL NYryc2lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorqTWM2OD1yLkKwOFg5KM7:TR?= M2r6OXNCVkeHUh?=
DSH1 NYKxdY9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\scGlEPTB;MD6yOFAxOSEQvF2= NXf0Tm91W0GQR1XS
HCE-4 NYTPO5FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsWVdnUUN3ME2wMlI3PDN7IN88US=> MX7TRW5ITVJ?
MZ2-MEL M1;1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID0WJZKSzVyPUCuNlg2OzdizszN NGLpdVBUSU6JRWK=
BL-41 Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnpUWV3UUN3ME2wMlI6OTJ|IN88US=> M4e4eXNCVkeHUh?=
HUTU-80 NXjRb4h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\LTWM2OD1yLkOxOFIh|ryP NGnRenJUSU6JRWK=
LOXIMVI NIr3UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfqS3lKSzVyPUCuN|E2ODNizszN MoPrV2FPT0WU
no-10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jLZWlEPTB;MD6zNVk{OSEQvF2= MXjTRW5ITVJ?
KARPAS-422 NVnWPYc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrPS2tKSzVyPUCuN|M6QTdizszN M3z1NHNCVkeHUh?=
SW684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLDU|JqUUN3ME2wMlM1QThizszN Mn;VV2FPT0WU
SF126 M37SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r6XmlEPTB;MD6zOVQyKM7:TR?= NVjlPWdiW0GQR1XS
D-263MG NWjqTWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\jS2lEPTB;MD6zOlIzPCEQvF2= NFrvdWFUSU6JRWK=
OVCAR-4 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIixOYFKSzVyPUCuN|c1OzNizszN MYLTRW5ITVJ?
BB49-HNC M4TnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UTWM2OD1yLkO4OVk6KM7:TR?= M1riTHNCVkeHUh?=
ONS-76 M4jHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXWRllKSzVyPUCuOFI6PTFizszN MlLsV2FPT0WU
MZ7-mel MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwNEe5NVEh|ryP NELkWG9USU6JRWK=
RCC10RGB NFW0bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIemlEPTB;MD60PVEyKM7:TR?= NVXsTY9oW0GQR1XS
BOKU NXzENlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrk[WxnUUN3ME2wMlQ6OTN|IN88US=> MX7TRW5ITVJ?
no-11 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13RNGlEPTB;MD61NFIzQCEQvF2= NHr6SoNUSU6JRWK=
IST-SL2 NUnNZmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jrOmlEPTB;MD61NFMxOiEQvF2= NGHHOXFUSU6JRWK=
RKO NYXPNIJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;wZpVKSzVyPUCuOVI6PjZizszN MoW4V2FPT0WU
HT-144 NGjKdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITjVJNKSzVyPUCuOVM3ODlizszN NYXKcnVJW0GQR1XS
NCI-H446 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i2dWlEPTB;MD62Nlc3KM7:TR?= NVfDSmxUW0GQR1XS
QIMR-WIL NHfhR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHUTWM2OD1yLkewOlI6KM7:TR?= NVPjZ4RZW0GQR1XS
MHH-PREB-1 M1TZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C3WWlEPTB;MD63OFQ3QSEQvF2= NVfI[WV1W0GQR1XS
EW-16 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jRPGlEPTB;MD63OlE4QCEQvF2= NHS1[pVUSU6JRWK=
EW-24 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwN{ixOlUh|ryP MkLnV2FPT0WU
LB373-MEL-D NUnaW2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGizV5BKSzVyPUCuPFI2ODhizszN M4T5OnNCVkeHUh?=
TE-9 NEjQPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmy[pRPUUN3ME2wMlg4PTN{IN88US=> MlnTV2FPT0WU
A3-KAW NV3KTpdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7D[HVKSzVyPUCuPVg1PTJizszN NWf4O4k5W0GQR1XS
A101D MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XRemlEPTB;MT6wN|A1OyEQvF2= MknPV2FPT0WU
OCUB-M M{fCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXGTWM2OD1zLkC0OFEzKM7:TR?= Mn3KV2FPT0WU
ES4 NIG3NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojzTWM2OD1zLkC1NVQ2KM7:TR?= M2iw[HNCVkeHUh?=
TE-6 NYTibo4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;oUmlEPTB;MT6yNVIzPiEQvF2= MXHTRW5ITVJ?
D-502MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K4bGlEPTB;MT6yN|M4PiEQvF2= NXexVJVGW0GQR1XS
KNS-42 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLxTWM2OD1zLkK0OFEzKM7:TR?= NH7xXmNUSU6JRWK=
SNU-C2B NUDBZlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzDTWM2OD1zLkOwOVg6KM7:TR?= NIm0cm9USU6JRWK=
NCI-H1838 M3Xie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofUTWM2OD1zLkOwO|M{KM7:TR?= NIjQWnJUSU6JRWK=
NKM-1 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX4TWM2OD1zLkOwPFU6KM7:TR?= M{\hN3NCVkeHUh?=
GI-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwM{[yNkDPxE1? NUXsbplxW0GQR1XS
NB5 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorOTWM2OD1zLkO5PFI4KM7:TR?= NVr5RWwxW0GQR1XS
CAS-1 M3jOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKxZXJSUUN3ME2xMlQxQTl{IN88US=> M3qx[HNCVkeHUh?=
HCE-T NWW1XplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17kXGlEPTB;MT61OlcyPCEQvF2= MV\TRW5ITVJ?
SBC-1 NUjxeW1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwNUe5PFQh|ryP NHvRbYlUSU6JRWK=
JiyoyeP-2003 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjUdo5KSzVyPUGuO|M1PjZizszN NWXKXphLW0GQR1XS
TE-5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO0NllKSzVyPUGuO|kyOzlizszN M1vjc3NCVkeHUh?=
CAN M3P5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwOEKyOVIh|ryP MUHTRW5ITVJ?
SK-UT-1 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\xdmlEPTB;Mj6xOlY6OyEQvF2= M2rjSXNCVkeHUh?=
JVM-2 NYj2clJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC2TWM2OD1{LkO2Nlg1KM7:TR?= M{j2NXNCVkeHUh?=
LB771-HNC NVy2cmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmKxTWM2OD1{LkW3OVUyKM7:TR?= NEnGTVlUSU6JRWK=
NCCIT NGfObGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XMUWlEPTB;Mj64OlYyPiEQvF2= NIH2T2pUSU6JRWK=
NCI-H2126 M2T3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwOEe1OVIh|ryP MlX6V2FPT0WU
Calu-6 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrBdnhKSzVyPUOuNFU4PDFizszN MVHTRW5ITVJ?
SK-LMS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nmTWlEPTB;Mz6xNVg5PiEQvF2= M1rzbHNCVkeHUh?=
ARH-77 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnqV|ZKSzVyPUOuOFY6OTVizszN M3jsbHNCVkeHUh?=
NB17 M3zlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLYd|lJUUN3ME2zMlY{QDR5IN88US=> NV3pVoFqW0GQR1XS
A253 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTLWnpKSzVyPUOuO|MzPDZizszN M37EWXNCVkeHUh?=
OPM-2 NFvae3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRwMke2PFUh|ryP NG\sSWZUSU6JRWK=
MV-4-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m4SmlEPTB;ND6zOlQ2PCEQvF2= MUTTRW5ITVJ?
SR MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwNEm5OVQh|ryP NHfLZlNUSU6JRWK=
KG-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknWTWM2OD12Lk[wPFQ2KM7:TR?= M4\kPHNCVkeHUh?=
OCI-AML2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf4[HFPUUN3ME21Mlg3OTV2IN88US=> NYX5UZgzW0GQR1XS
D-247MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTZwMUK1NVkh|ryP NGThUohUSU6JRWK=
DJM-1 NGrpNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jFSmlEPTB;Nj60PFU2QCEQvF2= MlLjV2FPT0WU
RPMI-6666 NV\3cWNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvsd2xKSzVyPUeuNlcxPjdizszN MUXTRW5ITVJ?
KARPAS-45 M2TuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HKRWlEPTB;Nz61NVY4OSEQvF2= M{LUNXNCVkeHUh?=
LP-1 NGHVWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDwXIx3UUN3ME23MlU1Pzh{IN88US=> NVTTRVduW0GQR1XS
RS4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4XGlEPTB;Nz62OVc5PyEQvF2= NELhOXhUSU6JRWK=
DU-4475 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwMkG2OVIh|ryP MUTTRW5ITVJ?
MONO-MAC-6 NInjR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS1TWM2OD16LkK3NFY3KM7:TR?= M1PYSHNCVkeHUh?=
NCI-SNU-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLJdoNKSzVyPUiuOVYyOjhizszN MUnTRW5ITVJ?
SJSA-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRThwN{K4NFUh|ryP NYD0Z3ZIW0GQR1XS
MMAC-SF NXvWOnZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWniR5VyUUN3ME24Mlc6OzB5IN88US=> MV\TRW5ITVJ?
SK-NEP-1 M2Hj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzLUGRTUUN3ME24Mlg6OTV3IN88US=> MVvTRW5ITVJ?
J-RT3-T3-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:2TWlEPTB;OD65OlUzQSEQvF2= Ml65V2FPT0WU
SKM-1 NFLqNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rE[2lEPTB;OT6wNVc{PCEQvF2= MXXTRW5ITVJ?
LB2241-RCC NGfCPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzlXHNKSzVyPUmuNFIxOTJizszN MUnTRW5ITVJ?
SIG-M5 NGK4eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTlwMEK0PVMh|ryP MmTJV2FPT0WU
EVSA-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDyTWM2OD17LkK3O|k{KM7:TR?= MkHDV2FPT0WU
GT3TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvITWM2OD17LkO1OVQ3KM7:TR?= MWfTRW5ITVJ?
NB6 NV;GUlV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXnRmtCUUN3ME25MlkzOjV7IN88US=> NHjncYRUSU6JRWK=
EHEB NVrRb4J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T1fmlEPTB;MUCuNFY2PiEQvF2= MXvTRW5ITVJ?
HEL M4nEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfETJJKSzVyPUGwMlQ4PzZizszN NVnaV4tGW0GQR1XS
ALL-PO NVjabXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrRR2RKSzVyPUGwMlc6OzhizszN MYnTRW5ITVJ?
TGW MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFzLkK4Nlgh|ryP MmnwV2FPT0WU
BC-3 NXHpUnliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi1RXBKSzVyPUGyMlEyOzhizszN NFnvNI9USU6JRWK=
IA-LM NIHsWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuTWM2OD1zMj60OFQ2KM7:TR?= NXi5S4p5W0GQR1XS
UACC-257 NHjNZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojXTWM2OD1zMj65NVk5KM7:TR?= Mk\EV2FPT0WU
KP-N-YS NFrMWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTCWJNKSzVyPUGyMlkzQDNizszN M{TOPXNCVkeHUh?=
Raji NGHNeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;mTWM2OD1zMz63OFk4KM7:TR?= M2XMPHNCVkeHUh?=
SF539 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDzWJRKSzVyPUGzMlg2PTdizszN NEXaSZlUSU6JRWK=
DMS-153 NVGyV3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TxfGlEPTB;MUSuNFAzQCEQvF2= NXi2bWQ2W0GQR1XS
L-540 NIfNdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK2bJlKSzVyPUG1MlA3PzJizszN MXjTRW5ITVJ?
MN-60 M1:wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ZUnpRUUN3ME2xOU4yQTd7IN88US=> MV\TRW5ITVJ?
RPMI-8866 NVnN[3hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLsTWM2OD1zNz60OFU1KM7:TR?= NYPn[FBoW0GQR1XS
NCI-H510A M4[5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF7LkO5O|Mh|ryP M4rJ[HNCVkeHUh?=
NB13 NWTGV5NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTyTWM2OD1zOT60PFc4KM7:TR?= Mm\kV2FPT0WU
HAL-01 NHS4SY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmqyTWM2OD1zOT63OVQ{KM7:TR?= MUTTRW5ITVJ?
NCI-H720 M{n6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z0ZmlEPTB;MkCuNlc{OyEQvF2= MUTTRW5ITVJ?
REH NUDzOpVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv2d5MxUUN3ME2yNE43OzV5IN88US=> MlvtV2FPT0WU
KNS-81-FD NIHjWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjXcndKSzVyPUKzMlE1PiEQvF2= MnHCV2FPT0WU
HC-1 NIjDdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLSTWM2OD1{ND61OVUyKM7:TR?= MXzTRW5ITVJ?
NCI-H2141 M1rUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnubYpKSzVyPUK0Mlc4PTRizszN MXvTRW5ITVJ?
MOLT-4 NH63bmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HFTmlEPTB;Mk[uOlc2OyEQvF2= M3PTUnNCVkeHUh?=
OMC-1 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LPZmlEPTB;MkeuNVQzOiEQvF2= MlnnV2FPT0WU
LC-1F NVTRWIRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXBdnRKSzVyPUK3MlMzPDVizszN M2X2V3NCVkeHUh?=
NCI-H1304 M17vU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ6LkG2Nlgh|ryP NGLL[FZUSU6JRWK=
BC-1 NUOwbYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XBW2lEPTB;MkiuOlUyKM7:TR?= NEPrdmdUSU6JRWK=
NCI-H64 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[4RZcxUUN3ME2yPU43OjV|IN88US=> MXnTRW5ITVJ?
MOLT-16 NYnTVII4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ7Lk[yPVIh|ryP M{XPUnNCVkeHUh?=
U-87-MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILqTHBKSzVyPUOwMlc3PiEQvF2= NVSxOWU{W0GQR1XS
GAK NGKxcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNzLkK2PFYh|ryP MUnTRW5ITVJ?
ES8 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP3ZVRmUUN3ME2zNk4yOjV{IN88US=> MnnwV2FPT0WU
HCC1599 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\1XpFKSzVyPUOyMlM{OjVizszN M33J[nNCVkeHUh?=
EB-3 M2jOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMSmlEPTB;M{SuN|EyPyEQvF2= NVH2NHIyW0GQR1XS
HCC1187 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rsUmlEPTB;M{WuPFA2OiEQvF2= MVnTRW5ITVJ?
SK-PN-DW M1\XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ncoZKSzVyPUO2MlE6PDNizszN NF3uenpUSU6JRWK=
JVM-3 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j6XWlEPTB;M{euNlM{QCEQvF2= NH\GV4JUSU6JRWK=
HCC2157 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTB[3VMUUN3ME2zO{46QTR4IN88US=> M{f5[nNCVkeHUh?=
A4-Fuk MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO2XoZKSzVyPUO4MlExODlizszN NIDyR2FUSU6JRWK=
COR-L279 M2rkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnzXXFMUUN3ME20NE4zQDVzIN88US=> NYH4dJc{W0GQR1XS
DEL Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ZTWM2OD12MT65NFg3KM7:TR?= M{fRUnNCVkeHUh?=
NCI-H1395 NU\s[nBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR{LkCxOlMh|ryP MnH4V2FPT0WU
MHH-NB-11 M2ThRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR|LkC4NVgh|ryP NF23eVdUSU6JRWK=
NCI-H2107 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzVeFBKSzVyPUSzMlQ5PDZizszN M1G5VHNCVkeHUh?=
NEC8 M2fDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\ad2lEPTB;NESuN|M3KM7:TR?= NEewRZdUSU6JRWK=
COLO-684 NVfrTFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3mO4tKSzVyPUS2MlIzPThizszN NHGzN3dUSU6JRWK=
LS-411N MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;5NXg6UUN3ME20PE41PzR6IN88US=> MV;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID